130 related articles for article (PubMed ID: 23734690)
21. Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness.
Cyrille NB; Villablanca PA; Ramakrishna H
Ann Card Anaesth; 2016; 19(2):214-6. PubMed ID: 27052059
[TBL] [Abstract][Full Text] [Related]
22. Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia.
Ribeiro AF; Nobre V; Neuenschwander LC; Teixeira AL; Xavier SG; Paula FD; Teixeira MM; Teixeira JC; Bittencourt H
Braz J Med Biol Res; 2013 Feb; 46(2):200-6. PubMed ID: 23369970
[TBL] [Abstract][Full Text] [Related]
23. Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia.
Korpelainen S; Intke C; Hämäläinen S; Jantunen E; Juutilainen A; Pulkki K
Dis Markers; 2017; 2017():9805609. PubMed ID: 28845081
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication.
Tognoli E; Luigi Giuseppe Leoni M; Morelli D; Sottotetti E; Martinetti A; Signoroni S; Galeone C; Gallino G
Wound Repair Regen; 2016 Nov; 24(6):1036-1040. PubMed ID: 27759946
[TBL] [Abstract][Full Text] [Related]
25. [TREATMENT OF SEPSIS IN NEUTROPENIC PATIENTS].
Zatezalo V; Šimec NJG
Acta Med Croatica; 2015 Sep; 69(3):153-9. PubMed ID: 29077369
[TBL] [Abstract][Full Text] [Related]
26. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
27. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
[TBL] [Abstract][Full Text] [Related]
28. The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Wach S; Al-Janabi O; Weigelt K; Fischer K; Greither T; Marcou M; Theil G; Nolte E; Holzhausen HJ; Stöhr R; Huppert V; Hartmann A; Fornara P; Wullich B; Taubert H
Int J Cancer; 2015 Sep; 137(6):1406-16. PubMed ID: 25754273
[TBL] [Abstract][Full Text] [Related]
29. Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis.
Nikkola A; Aittoniemi J; Huttunen R; Rajala L; Nordback I; Sand J; Laukkarinen J
Pancreas; 2017 Jan; 46(1):77-82. PubMed ID: 27841794
[TBL] [Abstract][Full Text] [Related]
30. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
31. Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.
Ni W; Han Y; Zhao J; Cui J; Wang K; Wang R; Liu Y
Sci Rep; 2016 Dec; 6():39481. PubMed ID: 27991579
[TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.
Haastrup E; Andersen J; Ostrowski SR; Høyer-Hansen G; Jacobsen N; Heilmann C; Ullum H; Müller K
Scand J Immunol; 2011 Apr; 73(4):325-9. PubMed ID: 21223347
[TBL] [Abstract][Full Text] [Related]
33. Correlation of Serum and Ascitic Fluid Soluble Form Urokinase Plasminogen Activator Receptor Levels With Patient Complications, Disease Severity, Inflammatory Markers, and Prognosis in Patients With Severe Acute Pancreatitis.
Long D; Wang Y; Wang H; Wu X; Yu L
Pancreas; 2019 Mar; 48(3):335-342. PubMed ID: 30768571
[TBL] [Abstract][Full Text] [Related]
34. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
35. Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?
Rivera-Caravaca JM; Esteve-Pastor MA
Thromb Haemost; 2019 Dec; 119(12):1891-1893. PubMed ID: 31805599
[No Abstract] [Full Text] [Related]
36. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
37. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
[TBL] [Abstract][Full Text] [Related]
38. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study.
Huttunen R; Syrjänen J; Vuento R; Hurme M; Huhtala H; Laine J; Pessi T; Aittoniemi J
J Intern Med; 2011 Jul; 270(1):32-40. PubMed ID: 21332843
[TBL] [Abstract][Full Text] [Related]
39. Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?
Enocsson H; Sjöwall C; Wetterö J
Clin Chim Acta; 2015 Apr; 444():234-41. PubMed ID: 25704300
[TBL] [Abstract][Full Text] [Related]
40. Infections of febrile neutropenic patients in malignant hematological diseases.
Rókusz L; Liptay L
Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
